These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7514702)

  • 21. Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.
    Muscari F; Guinard JP; Kamar N; Peron JM; Otal P; Suc B
    World J Surg; 2012 Aug; 36(8):1824-31. PubMed ID: 22532309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer.
    Mailey B; Artinyan A; Khalili J; Denitz J; Sanchez-Luege N; Sun CL; Bhatia S; Nissen N; Colquhoun SD; Kim J
    Arch Surg; 2011 Jan; 146(1):26-33. PubMed ID: 21242442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.
    Varona MA; Soriano A; Aguirre-Jaime A; Garrido S; Oton E; Diaz D; Portero J; Bravo P; Barrera MA; Perera A
    Transplant Proc; 2015; 47(1):84-9. PubMed ID: 25645778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
    Jiang L; Liao A; Yan L; Li B; Zhu W; Wen T
    Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for hepatocellular carcinoma recurrence: experience with 83 liver transplantation patients.
    Ataide EC; Boin IF; Almeida JR; Sevá-Pereira T; Stucchi RS; Cardoso AR; Caruy CA; Escanhoela CA
    Transplant Proc; 2011 May; 43(4):1362-4. PubMed ID: 21620130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
    World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of the risk factors influencing the prognosis of orthotopic liver transplantation for hepatocellular carcinoma and summary of relevant clinical experience].
    He YF; Fan J; Zhou J; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; Yang GH; Song K; Wang Z; Tang ZY; Wang YQ
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1232-5. PubMed ID: 16796877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era.
    Levi DM; Tzakis AG; Martin P; Nishida S; Island E; Moon J; Selvaggi G; Tekin A; Madrazo BL; Narayanan G; Garcia MT; Feun LG; Tryphonopoulos P; Skartsis N; Livingstone AS
    J Am Coll Surg; 2010 May; 210(5):727-34, 735-6. PubMed ID: 20421039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma.
    Kato H; Yoshida H; Taniguch H; Nomura R; Sato K; Suzuki I; Nakata R
    World J Gastroenterol; 2015 Dec; 21(46):13101-12. PubMed ID: 26673627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Correlation of perioperative alpha-fetoprotein expression in peripheral blood to recurrence of hepatocellular carcinoma].
    Shi M; Zhang Y; Zhong C; Lin XJ; Zhang CQ; Li JQ
    Ai Zheng; 2008 Jan; 27(1):83-7. PubMed ID: 18184471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma.
    Abdel-Wahab M; Sultan AM; Fathy OM; Salah T; Elshobary MM; Elghawalby NA; Yassen AM; Elsarraf WM; Elsaadany MF; Zalatah K
    Hepatogastroenterology; 2013; 60(128):1847-53. PubMed ID: 24719918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Significance of Preoperative Hepatocellular Carcinoma With High
    Yamao T; Yamashita YI; Imai K; Umezaki N; Tsukamoto M; Kitano Y; Arima K; Miyata T; Nakagawa S; Okabe H; Hayashi H; Chikamoto A; Ishiko T; Baba H
    Anticancer Res; 2019 Feb; 39(2):883-889. PubMed ID: 30711971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of combined preoperative fibrinogen and neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma after liver transplantation.
    Fu SJ; Ji F; Han M; Chen MG; Wang XP; Ju WQ; Zhao Q; Wu LW; Ren QQ; Guo ZY; Wang DP; Zhu XF; Ma Y; He XS
    Oncotarget; 2017 Jan; 8(3):4301-4312. PubMed ID: 27935864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
    Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
    Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Characteristics and Long-Term Outcome of Incidental Hepatocellular Carcinoma After Orthotopic Liver Transplant.
    Mourad MM; Algarni A; Aly MA; Gunson BK; Mergental H; Isaac J; Muiesan P; Mirza D; Perera MT; Bramhall SR
    Exp Clin Transplant; 2015 Aug; 13(4):333-8. PubMed ID: 26295183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation.
    Löhe F; Angele MK; Rentsch M; Graeb C; Gerbes A; Löhrs U; Beuers U; Jauch KW
    Clin Transplant; 2007; 21(6):696-701. PubMed ID: 17988261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.
    Zimmerman MA; Ghobrial RM; Tong MJ; Hiatt JR; Cameron AM; Hong J; Busuttil RW
    Arch Surg; 2008 Feb; 143(2):182-8; discussion 188. PubMed ID: 18283144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.